Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 18/20 | 0.64 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | CASP9 | P55211 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.56 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.54 |
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13177568 | 0.89 | TDP2 (0.64) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL3575982 | 0.78 | TDP2 (0.74) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL3563577 | 0.78 | TDP2 (1.00) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL3575463 | 0.78 | TDP2 (1.00) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL3573428 | 0.78 | TDP2 (0.78) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL3563253 | 0.78 | TDP2 (0.78) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL25826030 | 0.78 | TDP2 (0.64) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL25476124 | 0.77 | TDP2 (0.58) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL22525923 | 0.77 | TDP2 (0.58) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL3571638 | 0.77 | TDP2 (0.71) | TDP2CASP3CASP7CASP9CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | TDP2 2409/4885CASP3 2695/4885CASP7 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.